奧希替尼治療肺腺癌雙眼脈絡膜轉移1例_Chinese Journal of Ocular Fundus Diseases

Authors：

富月 , 陳曉敏 , 孫孔亮 ,  柯敏

武漢大學中南醫院眼科, 武漢 430071;

Corresponding?author：

柯敏, Email: keminyk@163.com

Keywords：

脈絡膜轉移; 肺腺癌; 表皮生長因子受體突變; 病例報告

DOI：

10.3760/cma.j.cn511434-20240122-00045

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 富月, 陳曉敏, 孫孔亮, 柯敏. 奧希替尼治療肺腺癌雙眼脈絡膜轉移1例. Chinese Journal of Ocular Fundus Diseases, 2024, 40(9): 724-726. doi: 10.3760/cma.j.cn511434-20240122-00045 Copy

1.	Westerwick D, Driever F, Le Guin CHD, et al. Intraocular metastases[J]. Pathologe, 2017, 38(6): 500-506. DOI: 10.1007/s00292-017-0373-y.
2.	Qu Z, Liu J, Zhu L, et al. A comprehensive understanding of choroidal metastasis from lung cancer[J]. Onco Targets Ther, 2021, 14: 4451-4465. DOI: 10.2147/OTT.S315532.
3.	Kreusel KM, Wiegel T, Stange M, et al. Choroidal metastasis in disseminated lung cancer: frequency and risk factors[J]. Am J Ophthalmol, 2002, 134(3): 445-447. DOI: 10.1016/s0002-9394(02)01580-5.
4.	Kreusel KM, Bechrakis NE, Wiegel T, et al. Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer[J]. Acta Ophthalmol, 2008, 86(5): 515-519. DOI: 10.1111/j.1600-0420.2007.01081.x.
5.	Contreras-Díaz M, Medina-Tapia A, Martínez-Bernal G, et al. Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib[J]. Arch Soc Esp Oftalmol, 2016, 91(11): 551-555. DOI: 10.1016/j.oftal.2016.03.002.
6.	Li C, Wang XE, Yan L, et al. Rapid vision improvement by using icotinib in a patient with bilateral choroidal metastases symmetrically from lung cancer[J]. Clin Respir J, 2023, 17(7): 647-653. DOI: 10.1111/crj.13649.
7.	Yamaoka M, Igarashi T, Shiratori N, et al. A case of binocular metastatic choroidal tumor originating from pulmonary adenocarcinoma successfully treated with molecular target therapy[J]. Case Rep Ophthalmol, 2023, 14(1): 426-432. DOI: 10.1159/000530130.
8.	Ye X, Kaliki S, Shields CL. Rapid regression of choroidal metastasis from lung cancer using erlotinib (Tarceva)[J]. Oman J Ophthalmol, 2014, 7(2): 75-77. DOI: 10.4103/0974-620X.137159.
9.	Inoue M, Watanabe Y, Yamane S, et al. Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib[J]. Eur J Ophthalmol, 2010, 20(5): 963-965. DOI: 10.1177/112067 211002000526.
10.	John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors[J]. Oncogene, 2009, 28(Suppl 1): S14-23. DOI: 10.1038/onc.2009.197.
11.	Guo H, Zhang J, Qin C, et al. Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives[J]. Cells, 2022, 11(20): 3200. DOI: 10.3390/cells11203200.
12.	Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725-737. DOI: 10.1038/s41416-019-0573-8.
13.	Popat S, Ahn MJ, Ekman S, et al. Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies[J]. Target Oncol, 2023, 18(1): 9-24. DOI: 10.1007/s11523-022-00941-7.
14.	Lamb YN. Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC[J]. Target Oncol, 2021, 16(5): 687-695. DOI: 10.1007/s11523-021-00839-w.
15.	Maller B, Salvatori S, Tanvetyanon T. Outcomes of intraocular metastasis from lung cancer in the era of targeted therapy: a systematic review and pooled analysis[J/OL]. Clin Lung Cancer, 2022, 23(8): e519-e525[2022-08-07]. https://pubmed.ncbi.nlm.nih.gov/36030188/. DOI: 10.1016/j.cllc.2022.07.018.
16.	Umeda I, Kitamura Y, Yokouchi H, et al. Effect of the first-line therapy with osimertinib for a metastatic choroidal tumor in advanced-stage lung cancer: a case report[J]. Case Rep Ophthalmol, 2023, 14(1): 331-339. DOI: 10.1159/000531255.
17.	Field MG, Boldt HC, Abu Hejleh T, et al. Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer[J/OL]. Am J Ophthalmol Case Rep, 2022, 26: 101459[2022-03-01]. https://pubmed.ncbi.nlm.nih.gov/35265776/. DOI: 10.1016/j.ajoc.2022.101459.
18.	N Vu A, Mehta UV, Israelsen P, et al. Treatment of choroidal metastasis from epidermal growth factor mutant non-small cell lung cancer with first-line Osimertinib therapy[J]. J Ophthalmic Vis Res, 2022, 17(1): 130-134. DOI: 10.18502/jovr.v17i1.10178.
19.	Keshwani K, Roelofs KA, Hay G, et al. Treating choroidal metastases and improving vision with osimertinib in EGFR T790M-mutated lung adenocarcinoma: a case report and review of the literature[J]. Ocul Oncol Pathol, 2021, 7(1): 26-30. DOI: 10.1159/000510602.

1. Westerwick D, Driever F, Le Guin CHD, et al. Intraocular metastases[J]. Pathologe, 2017, 38(6): 500-506. DOI: 10.1007/s00292-017-0373-y.
2. Qu Z, Liu J, Zhu L, et al. A comprehensive understanding of choroidal metastasis from lung cancer[J]. Onco Targets Ther, 2021, 14: 4451-4465. DOI: 10.2147/OTT.S315532.
3. Kreusel KM, Wiegel T, Stange M, et al. Choroidal metastasis in disseminated lung cancer: frequency and risk factors[J]. Am J Ophthalmol, 2002, 134(3): 445-447. DOI: 10.1016/s0002-9394(02)01580-5.
4. Kreusel KM, Bechrakis NE, Wiegel T, et al. Incidence and clinical characteristics of symptomatic choroidal metastasis from lung cancer[J]. Acta Ophthalmol, 2008, 86(5): 515-519. DOI: 10.1111/j.1600-0420.2007.01081.x.
5. Contreras-Díaz M, Medina-Tapia A, Martínez-Bernal G, et al. Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib[J]. Arch Soc Esp Oftalmol, 2016, 91(11): 551-555. DOI: 10.1016/j.oftal.2016.03.002.
6. Li C, Wang XE, Yan L, et al. Rapid vision improvement by using icotinib in a patient with bilateral choroidal metastases symmetrically from lung cancer[J]. Clin Respir J, 2023, 17(7): 647-653. DOI: 10.1111/crj.13649.
7. Yamaoka M, Igarashi T, Shiratori N, et al. A case of binocular metastatic choroidal tumor originating from pulmonary adenocarcinoma successfully treated with molecular target therapy[J]. Case Rep Ophthalmol, 2023, 14(1): 426-432. DOI: 10.1159/000530130.
8. Ye X, Kaliki S, Shields CL. Rapid regression of choroidal metastasis from lung cancer using erlotinib (Tarceva)[J]. Oman J Ophthalmol, 2014, 7(2): 75-77. DOI: 10.4103/0974-620X.137159.
9. Inoue M, Watanabe Y, Yamane S, et al. Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib[J]. Eur J Ophthalmol, 2010, 20(5): 963-965. DOI: 10.1177/112067 211002000526.
10. John T, Liu G, Tsao MS. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors[J]. Oncogene, 2009, 28(Suppl 1): S14-23. DOI: 10.1038/onc.2009.197.
11. Guo H, Zhang J, Qin C, et al. Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives[J]. Cells, 2022, 11(20): 3200. DOI: 10.3390/cells11203200.
12. Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725-737. DOI: 10.1038/s41416-019-0573-8.
13. Popat S, Ahn MJ, Ekman S, et al. Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies[J]. Target Oncol, 2023, 18(1): 9-24. DOI: 10.1007/s11523-022-00941-7.
14. Lamb YN. Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC[J]. Target Oncol, 2021, 16(5): 687-695. DOI: 10.1007/s11523-021-00839-w.
15. Maller B, Salvatori S, Tanvetyanon T. Outcomes of intraocular metastasis from lung cancer in the era of targeted therapy: a systematic review and pooled analysis[J/OL]. Clin Lung Cancer, 2022, 23(8): e519-e525[2022-08-07]. https://pubmed.ncbi.nlm.nih.gov/36030188/. DOI: 10.1016/j.cllc.2022.07.018.
16. Umeda I, Kitamura Y, Yokouchi H, et al. Effect of the first-line therapy with osimertinib for a metastatic choroidal tumor in advanced-stage lung cancer: a case report[J]. Case Rep Ophthalmol, 2023, 14(1): 331-339. DOI: 10.1159/000531255.
17. Field MG, Boldt HC, Abu Hejleh T, et al. Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer[J/OL]. Am J Ophthalmol Case Rep, 2022, 26: 101459[2022-03-01]. https://pubmed.ncbi.nlm.nih.gov/35265776/. DOI: 10.1016/j.ajoc.2022.101459.
18. N Vu A, Mehta UV, Israelsen P, et al. Treatment of choroidal metastasis from epidermal growth factor mutant non-small cell lung cancer with first-line Osimertinib therapy[J]. J Ophthalmic Vis Res, 2022, 17(1): 130-134. DOI: 10.18502/jovr.v17i1.10178.
19. Keshwani K, Roelofs KA, Hay G, et al. Treating choroidal metastases and improving vision with osimertinib in EGFR T790M-mutated lung adenocarcinoma: a case report and review of the literature[J]. Ocul Oncol Pathol, 2021, 7(1): 26-30. DOI: 10.1159/000510602.

Previous Article
系統性紅斑狼瘡繼發視網膜中央靜脈阻塞1例
Next Article
鞏膜扣帶手術后光感受器缺損1例

Chinese Journal of Ocular Fundus Diseases

奧希替尼治療肺腺癌雙眼脈絡膜轉移1例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content